JP2014240385A5 - - Google Patents

Download PDF

Info

Publication number
JP2014240385A5
JP2014240385A5 JP2014115617A JP2014115617A JP2014240385A5 JP 2014240385 A5 JP2014240385 A5 JP 2014240385A5 JP 2014115617 A JP2014115617 A JP 2014115617A JP 2014115617 A JP2014115617 A JP 2014115617A JP 2014240385 A5 JP2014240385 A5 JP 2014240385A5
Authority
JP
Japan
Prior art keywords
mab
fgfr2iiic
inhibits
fgfr2iiib
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014115617A
Other languages
English (en)
Japanese (ja)
Other versions
JP6342223B2 (ja
JP2014240385A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014240385A publication Critical patent/JP2014240385A/ja
Publication of JP2014240385A5 publication Critical patent/JP2014240385A5/ja
Application granted granted Critical
Publication of JP6342223B2 publication Critical patent/JP6342223B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014115617A 2008-11-07 2014-06-04 線維芽増殖因子受容体２に対するモノクローナル抗体 Active JP6342223B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11268608P 2008-11-07 2008-11-07
US61/112,686 2008-11-07
US16487009P 2009-03-30 2009-03-30
US61/164,870 2009-03-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011534932A Division JP5627591B2 (ja) 2008-11-07 2009-11-06 線維芽増殖因子受容体２に対するモノクローナル抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016152670A Division JP6445496B2 (ja) 2008-11-07 2016-08-03 線維芽増殖因子受容体２に対するモノクローナル抗体

Publications (3)

Publication Number Publication Date
JP2014240385A JP2014240385A (ja) 2014-12-25
JP2014240385A5 true JP2014240385A5 (cg-RX-API-DMAC7.html) 2015-02-12
JP6342223B2 JP6342223B2 (ja) 2018-06-13

Family

ID=42153600

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2011534932A Active JP5627591B2 (ja) 2008-11-07 2009-11-06 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2014115617A Active JP6342223B2 (ja) 2008-11-07 2014-06-04 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2016152670A Active JP6445496B2 (ja) 2008-11-07 2016-08-03 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2018223183A Active JP6661734B2 (ja) 2008-11-07 2018-11-29 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2020018719A Active JP6960485B2 (ja) 2008-11-07 2020-02-06 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2021166672A Active JP7301106B2 (ja) 2008-11-07 2021-10-11 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2023100475A Pending JP2023116746A (ja) 2008-11-07 2023-06-20 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2024193584A Pending JP2025032085A (ja) 2008-11-07 2024-11-05 線維芽増殖因子受容体２に対するモノクローナル抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011534932A Active JP5627591B2 (ja) 2008-11-07 2009-11-06 線維芽増殖因子受容体２に対するモノクローナル抗体

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2016152670A Active JP6445496B2 (ja) 2008-11-07 2016-08-03 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2018223183A Active JP6661734B2 (ja) 2008-11-07 2018-11-29 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2020018719A Active JP6960485B2 (ja) 2008-11-07 2020-02-06 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2021166672A Active JP7301106B2 (ja) 2008-11-07 2021-10-11 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2023100475A Pending JP2023116746A (ja) 2008-11-07 2023-06-20 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2024193584A Pending JP2025032085A (ja) 2008-11-07 2024-11-05 線維芽増殖因子受容体２に対するモノクローナル抗体

Country Status (20)

Country Link
US (8) US8101723B2 (cg-RX-API-DMAC7.html)
EP (4) EP2365828B1 (cg-RX-API-DMAC7.html)
JP (8) JP5627591B2 (cg-RX-API-DMAC7.html)
KR (1) KR101699432B1 (cg-RX-API-DMAC7.html)
CN (1) CN102131524B (cg-RX-API-DMAC7.html)
AU (1) AU2009313357B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0917315B8 (cg-RX-API-DMAC7.html)
CA (2) CA2733668C (cg-RX-API-DMAC7.html)
DK (3) DK2365828T3 (cg-RX-API-DMAC7.html)
ES (3) ES2646168T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20171640T1 (cg-RX-API-DMAC7.html)
HU (1) HUE035700T2 (cg-RX-API-DMAC7.html)
LT (2) LT3290052T (cg-RX-API-DMAC7.html)
MX (1) MX2011000455A (cg-RX-API-DMAC7.html)
NO (1) NO2842573T3 (cg-RX-API-DMAC7.html)
PL (3) PL2842573T3 (cg-RX-API-DMAC7.html)
PT (3) PT3290052T (cg-RX-API-DMAC7.html)
RU (1) RU2546254C9 (cg-RX-API-DMAC7.html)
SI (2) SI3290052T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010054265A2 (cg-RX-API-DMAC7.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
WO2012021841A2 (en) * 2010-08-12 2012-02-16 Attogen Inc. Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
WO2009100105A2 (en) * 2008-02-04 2009-08-13 Attogen Inc. Inhibitors of oncogenic isoforms and uses thereof
JP5627591B2 (ja) 2008-11-07 2014-11-19 ギャラクシー バイオテック， エルエルシー 線維芽増殖因子受容体２に対するモノクローナル抗体
CA2800311A1 (en) * 2010-05-11 2011-11-17 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
JP2015505850A (ja) * 2011-12-14 2015-02-26 シアトル ジェネティックス， インコーポレイテッド 新規な抗体薬物コンジュゲート（ａｄｃ）およびそれらの使用
DK2822968T3 (en) 2012-03-08 2018-04-16 Janssen Vaccines & Prevention Bv HUMAN BINDING MOLECULES ABLE TO BIND AND NEUTRALIZE INFLUENZA-B-VIRA, AND APPLICATIONS THEREOF
JP6188681B2 (ja) * 2012-04-09 2017-08-30 第一三共株式会社 抗ｆｇｆｒ２抗体
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
AU2013362937A1 (en) * 2012-12-21 2015-07-02 Janssen Biotech, Inc. Sensitive multiplex immunoassay for soluble fibroblast growth factor receptors
CN103145843B (zh) * 2013-02-20 2014-10-29 暨南大学 抗成纤维细胞生长因子受体的单链抗体
MX2015011428A (es) 2013-03-06 2016-02-03 Genentech Inc Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
NZ715201A (en) * 2013-08-01 2021-12-24 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
JP6509735B2 (ja) * 2013-10-08 2019-05-08 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤の組合せ
CN103757026B (zh) * 2013-12-20 2017-04-05 广州圣露生物技术有限公司 FGFR2b胞外段的基因序列、多肽及其应用
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
CN104231079A (zh) * 2014-09-12 2014-12-24 暨南大学 一种靶向bFGF高亲和力受体结合位点的抗体及其应用
TW201642904A (zh) * 2015-04-08 2016-12-16 第一三共股份有限公司 含抗ｆｇｆｒ２抗體及其他藥劑之組成物
WO2016171107A1 (ja) * 2015-04-20 2016-10-27 第一三共株式会社 Ｆｇｆｒ２の検出
RU2638457C2 (ru) * 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
CA3004794A1 (en) * 2015-11-23 2017-06-01 Five Prime Therapeutics, Inc. Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
AU2017233121B2 (en) 2016-03-15 2023-12-21 Itabmed (Hk) Limited Multispecific Fab fusion proteins and use thereof
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
SG10202112636SA (en) 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
US11603401B2 (en) 2017-06-02 2023-03-14 Ablynx N.V. Aggrecan binding immunoglobulins
JP7280254B2 (ja) 2017-10-24 2023-05-23 マジェンタ セラピューティクス インコーポレイテッド Ｃｄ１１７＋細胞を減少させるための組成物及び方法
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
TW201922782A (zh) 2017-10-24 2019-06-16 美商麥珍塔治療學股份有限公司 去除cd117+細胞之組合物及方法
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
CN112804989A (zh) 2018-10-05 2021-05-14 戊瑞治疗有限公司 抗fgfr2抗体制剂
CA3160812A1 (en) * 2019-12-24 2021-07-01 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
CA3160811A1 (en) * 2019-12-24 2021-07-01 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
EP4161566A4 (en) * 2020-06-03 2024-06-12 The Broad Institute, Inc. ANTAGONISTIC BIPARATOPIC ANTIBODIES THAT SPECIFICALLY BIND FIBROBLAST GROWTH FACTOR RECEPTOR 2 AND METHODS OF USE THEREOF
EP4232481A1 (en) 2020-10-22 2023-08-30 Regeneron Pharmaceuticals, Inc. Anti-fgfr2 antibodies and methods of use thereof
US20240101683A1 (en) * 2020-12-29 2024-03-28 Shenzhen Forward Pharmaceuticals Co., Limited Anti-FGFR2 Antibody and Use Thereof
EP4414387A4 (en) * 2021-10-08 2025-10-29 Shenzhen Forward Pharmaceuticals Co Ltd ANTI-FGFR2 ANTIBODY WITH IMPROVED ADCC AND ITS USE
TW202342527A (zh) 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
KR20250099773A (ko) * 2022-09-30 2025-07-02 3에이치 파머슈티컬즈 컴퍼니 리미티드 항-fgfr2b 항체 및 이의 용도
TW202442685A (zh) * 2023-04-28 2024-11-01 大陸商武漢人福創新藥物研發中心有限公司 抗FGFR2b單抗
WO2024240107A1 (zh) * 2023-05-19 2024-11-28 广东东阳光药业股份有限公司 一种抗fgfr2抗体及其应用
WO2024255756A1 (zh) * 2023-06-13 2024-12-19 南京维立志博生物科技股份有限公司 基于共同轻链产生双特异性抗体的方法
TW202527998A (zh) * 2023-12-18 2025-07-16 大陸商山東先聲生物製藥有限公司 抗FGFR2b抗體-藥物綴合物及其應用
WO2025218662A1 (zh) * 2024-04-16 2025-10-23 杭州中美华东制药有限公司 抗成纤维细胞生长因子受体2b的抗体及其用途
WO2025232811A1 (zh) * 2024-05-09 2025-11-13 正大天晴药业集团股份有限公司 靶向成纤维细胞生长因子受体2IIIb的抗体及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU638734B2 (en) 1989-07-06 1993-07-08 Regents Of The University Of California, The Receptors for fibroblast growth factors
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5620889A (en) * 1993-10-14 1997-04-15 Immunex Corporation Human anti-Fas IgG1 monoclonal antibodies
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6323316B1 (en) 1996-06-18 2001-11-27 The United States Of America As Represented By The Secretary Of The Department Of And Human Services Fibroblast growth factor receptor activating gene 1 and related compositions and methods
US20030143676A1 (en) * 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
JP2001302699A (ja) 2000-04-17 2001-10-31 Nichirei Corp ヒトｋｇｆｒに対する抗体
US20020115603A1 (en) 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
KR100945108B1 (ko) * 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
WO2003063893A2 (en) 2002-01-31 2003-08-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Fgfr agonists
KR100493460B1 (ko) * 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
EP2341067A1 (en) 2003-07-18 2011-07-06 Amgen, Inc Specific binding agents to hepatocyte growth factor
US20070248605A1 (en) * 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
WO2005115363A2 (en) 2004-05-25 2005-12-08 Yale University Method for treating skeletal disorders resulting from fgfr malfunction
WO2007114896A2 (en) 2006-03-31 2007-10-11 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
WO2007134210A2 (en) * 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
NZ573818A (en) 2006-06-02 2011-09-30 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
NZ573819A (en) 2006-06-02 2011-09-30 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
CA2655504A1 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
ME02371B (me) 2006-09-29 2016-06-20 Oncomed Pharm Inc Sastojci i postupci za dijagnstikovanje i tretman raka
EP2094733A1 (en) * 2006-11-03 2009-09-02 U3 Pharma GmbH Fgfr4 antibodies
ES2600882T3 (es) * 2007-03-23 2017-02-13 The Translational Genomics Research Institute Procedimiento de clasificación del cáncer de endometrio
US20110091473A1 (en) 2007-10-22 2011-04-21 Genmab A/S Novel antibody therapies
WO2009100105A2 (en) 2008-02-04 2009-08-13 Attogen Inc. Inhibitors of oncogenic isoforms and uses thereof
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
JP5627591B2 (ja) 2008-11-07 2014-11-19 ギャラクシー バイオテック， エルエルシー 線維芽増殖因子受容体２に対するモノクローナル抗体
US20120301482A1 (en) 2009-08-25 2012-11-29 National Jewish Health Methods and compositions for treatment of lung injury

Similar Documents

Publication Publication Date Title
JP2014240385A5 (cg-RX-API-DMAC7.html)
CY1122840T1 (el) Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
ES2523194T3 (es) Anticuerpo monoclonal humano específico para cada tumor
MX2024013960A (es) Anticuerpos anti-ox40 y metodos de uso
JP2019518742A5 (cg-RX-API-DMAC7.html)
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
JP2013198490A5 (cg-RX-API-DMAC7.html)
EP3712178A4 (en) ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
JP2014205674A5 (cg-RX-API-DMAC7.html)
EP4048309A4 (en) HUMANIZED ANTIBODIES AGAINST TNF-LIKE LIGAND 1A (TL1A) AND THEIR USES
IL291545A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
EP3929214A4 (en) ANTIBODY OR CHIMERIC ANTIGEN RECEPTOR TARGETING CLAUDIN 18.2
WO2016201389A3 (en) Anti-cd33 antibodies and methods of use thereof
WO2016201388A3 (en) Anti-cd33 antibodies and methods of use thereof
DK3389699T5 (da) Kimæriske og humaniserede anti-humane CTLA4-monoklonale antistoffer og anvendelser deraf
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
EP4032550A3 (en) Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
MX370848B (es) Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso.
MX2015011772A (es) Anticuerpos anti-hepcidina y usos de los mismos.
JP2013241409A5 (cg-RX-API-DMAC7.html)
CL2018003608A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703)